This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oh, J.
Right arrow Articles by Hughes, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oh, J.
Right arrow Articles by Hughes, S. H.

 Previous Article

Journal of Virology, November 2008, p. 11480-11483, Vol. 82, No. 22
0022-538X/08/$08.00+0     doi:10.1128/JVI.01353-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Integration of Rous Sarcoma Virus DNA: a CA Dinucleotide Is Not Required for Integration of the U3 End of Viral DNA{triangledown} ,{dagger}

Jangsuk Oh,1,2 Kevin W. Chang,2,3 and Stephen H. Hughes2*

Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, Bethesda, Maryland,1 HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, Maryland 21702-1201,2 Office of Technology Transfer, NIH, Rockville, Maryland3

Received 27 June 2008/ Accepted 22 August 2008

The two ends of RSV linear DNA are independently inserted into host DNA by integrase in vivo. We previously showed that the range of U3 sequences that are acceptable substrates for integrase appeared to be greater than the range of acceptable U5 sequences in vivo. We have done additional experiments to determine which U3 sequences are good integrase substrates. On the U3 end, there does not appear to be a stringent requirement for the canonical CA, integrase can efficiently remove three nucleotides, and six nucleotides are sufficient to allow integration with reasonable, albeit reduced, efficiency.

* Corresponding author. Mailing address: HIV Drug Resistance Program, NCI at Frederick, P.O. Box B, Bldg. 539, Rm. 130A, Frederick, MD 21702-1201. Phone: (301) 846-1619. Fax: (301) 846-6966. E-mail: hughes{at}ncifcrf.gov

{triangledown} Published ahead of print on 3 September 2008.

{dagger} Supplemental material for this article may be found at http://jvi.asm.org/.

Journal of Virology, November 2008, p. 11480-11483, Vol. 82, No. 22
0022-538X/08/$08.00+0     doi:10.1128/JVI.01353-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»